Back

The PVT1, HULC, and HOTTIP expression changes due to treatment in Diffuse Large B-cell lymphoma

Shahsavari, M.; Arbabian, S.; Hosseini, F.; Razavi, M. R.

2024-08-07 cancer biology
10.1101/2024.08.05.606587 bioRxiv
Show abstract

Diffuse large B-cell lymphoma is the most common histological subtype of non-Hodgkins lymphomas. It is an aggressive malignancy that displays great heterogeneity in morphology, genetics, biological behavior and treatment response owing to chromatin remodeling and epigenetics. Bioinformatic-based approaches were used to understand the possible signaling pathways of the three lncRNAs PVT1, HULC, and HOTTIP. Furthermore, their expression levels were quantitatively evaluated in 100 patients before and after the treatment. The results revealed that gene expression was significantly upregulated in PVT1, HULC, and HOTTIP by 7.39{+/-}8.48-, 5.924{+/-}7.536-, and 4.137{+/-}5.863 fold, respectively, relative to normal cases. Post-treatment measurement of lncRNA expression indicated that PVT1 and HOTTIP were significantly downregulated. Interestingly, the expression levels of PVT1, HULC, and HOTTIP were significantly higher in DLBCL patients aged > 60 years than in those aged < 60 years. In addition, there was a significant positive correlation between HULC and HOTTIP expression. The analysis of overexpressed lncRNA-miRNA interaction indicated different deregulated miRNA targets and the protein targets of upregulated lncRNAs are mainly with histone modification, DNA methylation/demethylation, and protein methyltransferase activity. Summary blurbThe lncRNAs PVT1, HULC, and HOTTIP expression is significantly upregulated before treatment and reduce to normal level after treatment. It can be used as diagnostic marker or prognostic means especially in Relapsed/refractory DLBCL.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Molecular Biology Reports
21 papers in training set
Top 0.1%
7.9%
2
Computational Biology and Chemistry
28 papers in training set
Top 0.1%
7.9%
3
PLOS ONE
5266 papers in training set
Top 23%
7.3%
4
PeerJ
308 papers in training set
Top 0.6%
6.3%
5
Frontiers in Oncology
103 papers in training set
Top 0.6%
5.5%
6
International Journal of Molecular Sciences
494 papers in training set
Top 2%
4.1%
7
Gene Reports
14 papers in training set
Top 0.1%
4.1%
8
Frontiers in Genetics
230 papers in training set
Top 1%
3.3%
9
Gene
46 papers in training set
Top 0.4%
3.2%
10
Biomedicines
67 papers in training set
Top 0.5%
2.7%
50% of probability mass above
11
Bioscience Reports
27 papers in training set
Top 0.4%
2.4%
12
Scientific Reports
3612 papers in training set
Top 47%
2.1%
13
BioMed Research International
28 papers in training set
Top 0.8%
2.0%
14
Biochemistry and Biophysics Reports
30 papers in training set
Top 0.3%
2.0%
15
Cancers
213 papers in training set
Top 3%
1.7%
16
BMC Cancer
67 papers in training set
Top 1%
1.5%
17
Cancer Medicine
26 papers in training set
Top 0.6%
1.5%
18
Heliyon
152 papers in training set
Top 4%
1.4%
19
Medicine
31 papers in training set
Top 1%
1.3%
20
Cells
249 papers in training set
Top 4%
1.3%
21
Journal of Clinical Medicine
97 papers in training set
Top 3%
1.3%
22
Frontiers in Immunology
638 papers in training set
Top 7%
1.1%
23
Genes
144 papers in training set
Top 3%
1.1%
24
Genes to Cells
25 papers in training set
Top 0.3%
1.1%
25
RNA Biology
78 papers in training set
Top 0.9%
1.1%
26
Journal of Cellular Biochemistry
11 papers in training set
Top 0.1%
1.1%
27
eLife
5828 papers in training set
Top 60%
1.0%
28
Journal of Cellular and Molecular Medicine
20 papers in training set
Top 0.5%
1.0%
29
Experimental Cell Research
28 papers in training set
Top 0.5%
1.0%
30
Cell Death & Disease
126 papers in training set
Top 3%
0.8%